- Trial phase
- Approved
- Time to market
- Already approved and marketed since October 2019 (US).
- Why 4/10
- Trikafta is already FDA-approved and commercially dominant with no pending regulatory decision or pivotal readout for this drug itself in the next ~12 months. The April 2026 label extension has already passed. Per the rubric, an approved/commercialized drug with no upcoming binary catalyst earns a score of 3-5; given Trikafta remains Vertex's largest product (~85% of revenue), the default of 4 is appropriate.
Trikafta itself has no pending regulatory catalyst. Watch Vertex's Q3 2026 earnings (today, Nov 2) for any CF revenue trends and management commentary on the Alyftrek transition, plus the November 30 PDUFA for povetacicept in IgA nephropathy. The CF Buyers' Club/Beximco generic effort ("Triko") is a developing patient-access story but faces US importation-law barriers and no near-term patent disruption given protection into 2037-2038.
Price Chart
Executive Summary
Trikafta (elexacaftor/tezacaftor/ivacaftor) is Vertex Pharmaceuticals' blockbuster triple-combination therapy for cystic fibrosis, approved since 2019. It generated $10.3 billion in 2025 revenue, representing 85% of Vertex's total sales. In April 2026, the FDA expanded its label to cover approximately 95% of all US CF patients. The drug carries a boxed warning for liver injury (updated June 2026). While still dominant, Trikafta's sales growth is flattening as Vertex transitions patients to its next-gen CF drug Alyftrek and faces emerging generic access efforts abroad. Patent protection extends to 2037-2038, keeping US generic competition at bay. With no pending regulatory catalyst specific to Trikafta itself, the drug is a steady cash generator but not a near-term binary event driver.
How It Works
Trikafta is a three-drug combination pill (elexacaftor, tezacaftor, ivacaftor) that treats cystic fibrosis at its root cause. Cystic fibrosis is caused by a faulty CFTR protein that fails to move chloride (salt) properly in cells. Trikafta's components work together to fix the defective protein's folding and function, restoring salt and water balance in the lungs and other organs. Two drugs (elexacaftor and tezacaftor) help the cell make more of the CFTR protein and get it to the right place, while the third (ivacaftor) keeps the channel open longer.
Trial Status
Trikafta is FDA-approved for cystic fibrosis in patients aged 2 years and older with responsive CFTR gene variants. The April 2026 label expansion added eligibility for any CFTR variant that results in CFTR protein production, adding roughly 800 rare variants. Vertex continues to run long-term safety extension studies.
The Two-Sided Case
Upcoming Catalysts
- No Trikafta-specific PDUFA or pivotal readout is scheduled. Key Vertex-level catalysts: Q3 2026 earnings (Nov 2, after close) and the November 30, 2026 PDUFA for povetacicept in IgA nephropathy (a non-CF pipeline drug).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report